Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies approved by the FDA for psoriasis treatment. Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging. METHODS: We conducted a literature s...

Descripción completa

Detalles Bibliográficos
Autores principales: Farahnik, Benjamin, Beroukhim, Kourosh, Abrouk, Michael, Nakamura, Mio, Zhu, Tian Hao, Singh, Rasnik, Lee, Kristina, Bhutani, Tina, Koo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906115/
https://www.ncbi.nlm.nih.gov/pubmed/27221323
http://dx.doi.org/10.1007/s13555-016-0121-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906115/
https://www.ncbi.nlm.nih.gov/pubmed/27221323
http://dx.doi.org/10.1007/s13555-016-0121-x

Ejemplares similares